NRx Pharmaceuticals Announces the Appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP, Senior Vice President of Clinical Development and Medical Affairs

• Extensive global pharmaceutical leadership experience in clinical development, operations, and medical affairs
• Focused psychiatry practice expert in PTSD, Affective Disorders and Schizophrenia
• Proven track record in research as an investigator and academic grant-funded researcher
• Visiting Scholar at Stanford University, Center for Precision Mental Health and Wellness
• Former roles at Boehringer Ingelheim and Pendulum Therapeutics

RADNOR, Pa., Dec. 5, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", the "Company"), a clinical-stage central nervous system (CNS) biopharmaceutical company, today announced the appointment of Carrie M. Carretta, PhD, APN-BC, AHN-BC, PMHNP as Senior Vice President, Clinical Development and Medical Affairs.  She will lead the Company's clinical development program and provide medical oversight across all indications. Dr. Carretta will report to the Chief Executive Officer and Director. 

"The NRx team is excited to have attracted a clinician with deep experience as an investigator.  Dr. Carretta's wealth of knowledge will help drive our mission to develop a first-in-class lifesaving drug for suicidal depression and PTSD.  She has invaluable experience in both front-line care and corporate drug development that will benefit both patients and shareholders.", said Stephen Willard, Chief Executive Officer, and Director, NRx Pharmaceuticals.

Dr. Carretta has extensive leadership experience in the pharmaceutical industry, developing and executing strategies in medical, clinical scientific and regulatory affairs as well as hiring, developing, and managing diverse medical science and clinical teams globally.  She brings with her an extensive network of key opinion leaders, health care providers and researchers worldwide.

Dr. Carretta is the co-founder and managing partner at C&G Holdings, LLC and most recently worked for Boehringer Ingelheim Pharmaceuticals as the Executive Director, Therapeutic Area Head for Clinical Development and Medical Affairs leading the CNS and Ophthalmology areas. Prior to this role, Dr. Carretta served as the Vice President, Medical and Scientific Affairs at Pendulum Therapeutics.

Prior leadership roles at Juul Labs included developing infrastructure and strategies which supported the company's consumer device and her work for Novartis contributed to medical excellence for Cosentyx^®, Ilaris®, Entresto® and Kisquali^®, with Bayer Pharmaceuticals for The Betaconnect™ autoinjector used with Betaseron^®, and with Teva Pharmaceuticals for Adasuve^®.

In addition to her experience in the pharmaceutical industry, Dr. Carretta has acted as an investigator for numerous clinical trials and has worked extensively in clinical practice both in general and forensic psychiatry, and in academia as a funded researcher.

Dr. Carretta holds a doctorate degree in Nursing from Vanderbilt University and both master's and bachelor's degrees in Nursing from Rutgers, The State University of New Jersey.  She is nationally board certified as an APN-BC, AHN-BC & PMHNP. Dr. Carretta is a current visiting scholar at Stanford University, Center for Precision Mental Health and Wellness.

NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of central nervous system disorders, specifically suicidal depression and post-traumatic stress disorder (PTSD). The company's lead program NRX-101, an oral, fixed-dose combination of D-cycloserine and lurasidone, targets the brain's NMDA receptor and is being investigated in a Phase 3 trial under a Food and Drug Administration ("FDA") Special Protocol Agreement and Breakthrough Therapy Designation in patients with bipolar depression and acute suicidal ideation, an indication for which the only approved treatment is electroshock therapy. NRx Pharmaceuticals has also initiated a Phase 2b clinical trial in patients with Sub-Acute Suicidality, potentially a substantially broader indication. The Breakthrough Therapy Designation and Special Protocol Agreement were awarded by the FDA based on the Company's prior STABIL-B trial that demonstrated substantial improvement over available therapy in reducing depression and suicidality compared to placebo when patients were treated with NRX-101 after a single dose of ketamine.

This announcement of NRx Pharmaceuticals, Inc. includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995, which may include, but are not limited to, statements regarding our financial outlook, product development, business prospects, and market and industry trends and conditions, as well as the Company's strategies, plans, objectives, and goals. These forward-looking statements are based on current beliefs, expectations, estimates, forecasts, and projections of, as well as assumptions made by, and information currently available to, the Company's management. 

The Company assumes no obligation to revise any forward-looking statement, whether as a result of new information, future events or otherwise. Accordingly, you should not place reliance on any forward-looking statement, and all forward-looking statements are herein qualified by reference to the cautionary statements set forth above.

CORPORATE CONTACT
Molly Cogan
Sr. Director, Global Communications
[email protected]

INVESTOR RELATIONS
Suzanne Messere
Investor Relations
[email protected]

SOURCE NRx Pharmaceuticals, Inc.